Skip to content

Press Releases

Jan 31, 2020
Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
–  Bempedoic Acid is an Oral, Once-Daily, Non-Statin Medicine that Lowers Bad Cholesterol with a First-in-Class Mechanism – –   Positive CHMP Opinion is Based on the Completed Pivotal Phase 3 LDL-Cholesterol Lowering Program – –   European Commission Decision on the Marketing Authorisation
Jan 31, 2020
Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
–  Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet is an Oral, Once-Daily, Non-Statin Medicine that Lowers Bad Cholesterol with a First-in-Class Mechanism  – –  Positive CHMP Opinion is Based on the Completed Pivotal Phase 3 Fixed Dose Combination Tablet LDL-Cholesterol Lowering Program  –
Jan 07, 2020
Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference
ANN ARBOR, Mich., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2020 at 12:00 p.m.
Jan 03, 2020
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on January 2, 2020, the Compensation Committee of Esperion’s Board of Directors granted 358 restricted stock units (RSUs) to one new colleague under Esperion’s 2017 Inducement Equity Incentive Plan.